BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,112,603 | +10.6% | 42,192 | -27.8% | 0.00% | 0.0% |
Q2 2023 | $1,005,685 | +123296.9% | 58,470 | +18.8% | 0.00% | 0.0% |
Q1 2023 | $815 | +136.2% | 49,202 | +8.6% | 0.00% | +100.0% |
Q4 2022 | $345 | -99.9% | 45,317 | -10.0% | 0.00% | -33.3% |
Q3 2022 | $500,000 | -17.5% | 50,363 | -24.7% | 0.00% | 0.0% |
Q2 2022 | $606,000 | -33.8% | 66,839 | -26.0% | 0.00% | -25.0% |
Q1 2022 | $915,000 | -95.1% | 90,288 | -91.9% | 0.00% | -95.3% |
Q4 2021 | $18,500,000 | -52.8% | 1,109,233 | +32.5% | 0.09% | -58.3% |
Q3 2021 | $39,224,000 | -22.7% | 836,914 | +0.6% | 0.21% | -28.0% |
Q2 2021 | $50,722,000 | +0.5% | 832,084 | +1.5% | 0.29% | -16.4% |
Q1 2021 | $50,488,000 | -8.6% | 819,632 | +5.5% | 0.34% | -18.2% |
Q4 2020 | $55,253,000 | – | 777,031 | – | 0.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |